Acadia Pharmaceuticals (ACAD) Q3 2026 earnings review
Acadia raises its sales outlook as its Rett drug accelerates
Acadia Pharmaceuticals, a maker of drugs for neurological disorders, grew faster in the third quarter as its newer Rett syndrome medicine gained traction. Revenue rose 22% excluding one-offs to $342 million, led by a 39% jump in DAYBUE sales after the launch of its powder version. Chief executive Catherine Owen Adams raised the full-year sales outlook and moved the company's experimental Alzheimer's psychosis drug into late-stage trials.
| Revenue, excluding one-offs | $342.3M +21.9% from a year ago |
|---|---|
| DAYBUE net sales | $140.1M +38.6% from a year ago |
| NUPLAZID sales, excluding one-offs | $202.2M +12.5% from a year ago |
| Full-year revenue outlook | Raised $10M middle of the range: $1.28B |
⚖️ Verdict: 🟢 Bullish
The story got better because the powder formulation of DAYBUE is lifting sales faster than planned, while a new U.S. patent extends protection to 2041 and European sales have begun in Germany. Lower research spending also boosted pre-tax profit by 80% by our math. One caution: the company described its mid-stage Alzheimer's psychosis trial as showing "consistent efficacy trends" without printing statistical proof, and it trimmed $15 million off the top of its full-year NUPLAZID outlook.
The question now is whether the Alzheimer's psychosis data is strong enough to win in late-stage trials and whether DAYBUE's surge comes from lasting new patients. Either the powder is bringing in patients who stayed away from the liquid, or it is a one-time wave of current patients switching over. The November 17 medical conference presentation on the Alzheimer's trial and fourth-quarter patient mix details will settle both debates.
🐂 Bull Case
DAYBUE Powder Formulation Lifts Growth to 39%
DAYBUE, Acadia's treatment for the rare neurological disorder Rett syndrome, is accelerating for a third consecutive quarter. Chief executive Catherine Owen Adams credited the jump to "meaningful uptake of DAYBUE STIX", a powder version launched earlier this year for patients who struggle with the liquid medicine.
Third-quarter sales reached $140.1 million, up 38.6% from a year ago, and the biotech group raised its full-year DAYBUE outlook by $17.5 million at the middle of the range to $505–520 million. Because DAYBUE grew three times faster than the company's older drug, its share of total revenue rose to 40.9%, up from 36.3% a year ago by our math.
What to watch: the share of STIX starts coming from brand-new or returning patients on the conference call. A high share of new patients would show the powder is expanding the market rather than just moving existing patients off the liquid.
European Launch and Patent Extension Build DAYBUE Durability
Acadia is expanding DAYBUE beyond the United States while locking in longer protection against generic copies. In August, the European Commission approved the drug under the name DAYBU, and the company launched it in Germany in early October with patients already receiving commercial supply.
In parallel, the specialist drugmaker completed a late-stage trial in Japan that supports a regulatory filing in 2027, and won a U.S. patent "covering weight-banded dosing of trofinetide" that extends domestic protection by nearly five years through March 2041. That gives the franchise more time to earn back its clinical investments.
What to watch: German reimbursement negotiations in mid-2027, when six months of free launch pricing end and negotiated prices take effect.
Pre-Tax Profit Nearly Doubled as Research Costs Fell
Headline net income fell 25.4% to $53.5 million, but that drop is an accounting mirage caused by a one-time $27.2 million tax benefit in the prior year. Before taxes, profit rose 80.4% to $80.4 million, lifting operating margin by 8.1 percentage points to 21.0% by our math.
- Research and development costs: 22.3% of revenue, down 9.2 percentage points from a year ago
- Selling, general and administrative costs: 46.5% of revenue, down 1.4 percentage points from a year ago
- Full-year research outlook: cut by $35 million at the middle of the range to $325–340 million
What to watch: fourth-quarter research spending, which by our math must rise 15.4% from a year ago to $97.8 million as late-stage trials enroll.
🐻 Bear Case
Remlifanserin Advances on Efficacy Trends While High-End NUPLAZID Trimmed
Acadia treats remlifanserin, an experimental drug for hallucinations and delusions in Alzheimer's and Lewy body dementia, as its next major growth engine alongside NUPLAZID, its medicine for Parkinson's disease psychosis. Chief executive Catherine Owen Adams said the group is "continuing Phase 3 development of remlifanserin based on Phase 2 results", while NUPLAZID grew on "underlying demand and the continued expansion of our commercial reach".
Yet the release described the mid-stage Alzheimer's trial as showing "consistent efficacy trends at the 60 mg dose across all four psychosis scales that were assessed for the full study population" without printing statistical significance or numerical scores. Meanwhile, NUPLAZID sales rose 12.5% excluding one-offs to $202.2 million, but the company trimmed $15 million off the top of its full-year NUPLAZID outlook, narrowing it to $760–775 million.
Advancing into late-stage trials on "trends" keeps clinical risk high ahead of full data, and the trimmed NUPLAZID ceiling shows the 30% sales-force expansion is taking longer to pay off than the top of the prior plan assumed. By our math, the new NUPLAZID midpoint implies 10.9% full-year growth against 2025 sales excluding one-offs, below the pace needed to reach $1 billion by 2028.
What to watch: the detailed RADIANT Phase 2 data presentation on November 17 in Boston. Investors need to see the exact effect sizes and p-values to judge whether the late-stage trial can succeed.
Royalty Mix and Sales Expansion Weigh on Gross Margin
While lower research bills helped the bottom line, the cost of making products and paying royalties took a larger bite out of sales. Cost of product sales rose 2.5 percentage points of revenue from a year ago to 10.3%, pulling gross margin down 2.5 percentage points to 89.7% by our math.
Because DAYBUE carries tiered royalty payments to its original developer and is growing much faster than NUPLAZID, every shift in sales mix toward DAYBUE trims the company's gross margin. At the same time, selling and administrative bills rose 19.3% from a year ago to $159.2 million to fund the bigger sales team and European launch.
What to watch: full-year gross-to-net discounts—the gap between list prices and what Acadia actually collects—in the quarterly filing, to see if higher rebates added to the royalty pressure.
Risks this quarter didn't answer
Several standing commercial, regulatory and legal questions received no new numbers in the third-quarter press release.
- DAYBUE patient counts and drop-out rates: omitted from the release, leaving unclear how much of the 38.6% growth came from price or inventory versus active patients.
- Medicare rebate adjustments: no new revision to Inflation Reduction Act rebate estimates occurred in Q3, though NUPLAZID remains eligible for government price negotiation in 2029.
- Research leadership transition: no successor was named in the release for the retiring head of research and development.
- Pending litigation: no update on the securities class action or the November 2026 Zydus patent trial; the quarterly Form 10-Q legal footnote will provide the latest status.
👓 Other Themes
U.S. Tax Law Lags Distort Net Income Comparisons
Federal tax law changes and Medicare inflation rebates continue to skew year-over-year comparisons. In the third quarter of 2025, Acadia booked a $27.2 million tax benefit after U.S. tax legislation restored immediate write-offs for domestic research spending, whereas this quarter carried a $26.9 million tax expense. Earlier Medicare rebate adjustments also reduced reported third-quarter 2025 NUPLAZID sales by $2.3 million.
💲 Other KPIs
Cash and investments rose by $20.0 million from last quarter and $156.8 million since the start of the year, up 15.3% from a year ago by our math. With no debt on the balance sheet, the growing cash pile gives the drugmaker room to fund late-stage trials and license new drugs.
Money owed by customers rose 39.0% from a year ago and 32.6% since December by our math, outpacing the 22.9% rise in reported revenue. Accounts receivable is cash billed to specialty pharmacies and distributors that Acadia has not yet collected, so a faster rise temporarily ties up working capital.
Diluted shares increased 2.8% from a year ago, continuing a steady climb from 170.7 million in the third quarter of 2025. Because the specialist drugmaker does not buy back stock, employee stock compensation gradually dilutes existing shareholders.
🔮 Guidance
Raised. Acadia lifted the middle of its full-year revenue plan by $10 million, pointing to 18.2% growth over 2025 sales excluding one-offs by our math. That leaves $361.7 million for the fourth quarter, up 21.3% against last year's clean base (or 27.4% against reported Q4 2025 sales). This is the second raise this year: +$0M, +$20M, +$10M.
Raised. The middle of the outlook moved up $17.5 million to $512.5 million, or 30.9% growth for the year by our math. After $366.1 million in the first nine months, the plan leaves $146.4 million for the fourth quarter, up 33.6% from a year ago and including initial commercial sales in Germany. Move cadence this year: +$0M, +$20M, +$17.5M.
Cut. Management kept the $760 million floor but trimmed $15 million off the top, lowering the middle of the range by $7.5 million to $767.5 million. By our math, that leaves $215.2 million for the fourth quarter, up 14.1% from last year's clean fourth quarter (and 23.4% above the rebate-depressed GAAP figure).
Cut. The company lowered its full-year research budget by $35 million at the middle of the range, following a $30 million reduction last quarter: +$0M, -$30M, -$35M. By our math, the new $332.5 million midpoint still leaves $97.8 million of spending for the fourth quarter, up 15.4% from a year ago and 28.2% above the third quarter.
Cut. Acadia narrowed the range and lowered the middle of the plan by $5 million to $675 million, which is still 23.0% higher than in 2025 by our math. After $490.5 million in the first nine months, the outlook implies $184.5 million of spending in the fourth quarter, up 18.6% from a year ago.
❓ Key Questions
What did the Phase 2 Alzheimer's psychosis scores actually show?
The release noted "consistent efficacy trends" at the 60 mg dose of remlifanserin without giving p-values or effect sizes. Investors need to know whether the primary endpoint was statistically significant before Phase 3 costs ramp up.
How many STIX patients are new versus switching from liquid?
DAYBUE sales rose 38.6%, but the release gave no patient counts or switcher percentages. If most STIX demand comes from existing patients switching formulations or temporary restarts, growth will slow once the current base converts.
Why did Acadia trim the top of the NUPLAZID outlook?
Management cut the upper end of full-year NUPLAZID sales by $15 million despite 12.5% growth in the third quarter. Was the trim driven by slower prescribing from the expanded sales force, lower refill rates, or higher Medicare rebates?
How much European DAYBU revenue is in the fourth-quarter plan?
Acadia launched DAYBU in Germany in early October and raised the full-year franchise outlook by $17.5 million at the middle of the range. Separating German launch stocking from U.S. demand will show the true domestic run-rate.